WADA approves 2011 List of Prohibited Substances
Montreal: The World Anti-Doping Agency has
approved the list of prohibited substances for 2011 with
several changes made from previous year, including addition of
a section to address abuse of pharmacological substances,
removal of mandatory Declaration of Use for specific
substances not prohibited.
The WADA Executive Committee also reviewed the
controversial "whereabouts" clause which required the athletes
to give information about their location to the International
Sport Federation (IF) or National Anti-Doping Organisation
(NADO) three months in advance.
The new List will now be made official and published by
October 1, 2010. It will take effect on January 1, 2011.
"The annual revision of the List is a consultative
process facilitated by WADA, beginning with the circulation of
a draft List among stakeholders," WADA said in a statement.
"Comments received are considered by WADA`s List Expert
Group, which then presents its conclusions to WADA`s Health,
Medical and Research Committee. The latter in turn submits its
final recommendations to the Executive Committee, which
discusses the recommendations and makes a final decision at
its September meeting," it said.
"The Prohibited List is one of the cornerstones of the
harmonised fight against doping. It specifies substances and
methods prohibited in sport. Its implementation is mandatory
for organisations that have adopted the WADA Code," it added.
WADA President John Fahey said the list was approved
through consensus of the stakeholders.
"Thanks to the input from international scientific
experts and stakeholders, the 2011 List once again reflects
the latest scientific advances and broad consensus in the
anti-doping community," said Fahey.
"As in previous years, changes are founded on expanding
anti-doping knowledge, evidence from the field, and constantly
growing understanding of doping practices and trends. This is
a dynamic and successful process. As the facilitator of this
process, WADA thanks all those who have contributed by
providing expertise and feedback," he said.
"WADA constantly looks at ways of improving and enhancing
the global fight against doping in sport. We have to challenge
ourselves and those who fight against doping in general," said
WADA`s Director General David Howman.
A new section -- `Non-Approved Substances` -- has been
added to the 2011 list. This `open` section addresses the
issue of the abuse of pharmacological substances for the
purpose of performance enhancement that are not included in
other sections of the List and that are not approved by any
governmental regulatory health authority for human therapeutic
use (i.e. drugs under pre-clinical or clinical development or
discontinued). These substances will be prohibited at all
times (in and out-of-competition).
In addition, platelet-derived preparations (commonly
referred as PRP), which are currently prohibited when used by
intra-muscular route, have been removed from the 2011 List
after consideration of the lack of current evidence concerning
the use of these methods for purposes of performance
WADA said current studies on platelet-derived
preparations do not demonstrate potential for performance
enhancement beyond a potential therapeutic effect.
Another amendment was the removal of the obligation for
athletes to file a Declaration of Use for specific substances
that are not prohibited.
Declarations of Use, as distinguished from Therapeutic
Use Exemptions (allowing use of prohibited substance), are
currently required for salbutamol, salmeterol by inhalation;
glucocorticosteroids administered by intra-articular,
periarticular, peritendinous, epidural, intradermal and
inhalation routes; as well as platelet-derived preparations
that are not administered by intramuscular route.
Failure by an athlete to file a Declaration of Use does
not currently result in an allegation of an anti-doping rule
violation. This administrative requirement was therefore
The Executive Committee also reviewed an Introductory
Note on Athlete Whereabouts Requirements.
"Introductory Note helps further clarify the rationale
for collecting athlete whereabouts information and assists
anti-doping organisations in the practical implementation of
the requirements," WADA said.
WADA said it will continue to consult with athletes and
Code signatories and present potential recommendations for
practical improvements on how whereabouts requirements are
applied on an ongoing basis at the November meetings of WADA`s
Executive Committee and Foundation Board.
"Over the past few months, WADA has conducted a review of
practical implementation of athlete whereabouts requirements
by International Federations (IFs) and National Anti-Doping
Organisations (NADOs) to assess how World Anti-Doping Code
signatories have enforced whereabouts requirements under the
Code and how they have exercised their discretion in the
management of Registered Testing Pools," WADA said.
Results of survey circulated to anti-doping organisations
by WADA earlier this year showed that Code signatories
overwhelmingly support the principle of whereabouts and
reported successful implementation of the rules. The survey
also indicated that there is still some misunderstanding from
a number of anti-doping organisations as to the purpose of
whereabouts requirements, it said.
The Executive Committee will hold its next meeting on
November 20 here. The Foundation Board will meet the following